Alto Neuroscience, Inc. Investment Income, Interest
Alto Neuroscience, Inc. (ANRO) reported Investment Income, Interest of $2.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Alto Neuroscience, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.11M, a 25.49% increase year-over-year.
- Alto Neuroscience, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.56M, a 14.56% decline year-over-year.
- Alto Neuroscience, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.56M, a 26.89% decline year-over-year.
- Alto Neuroscience, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.53M, a 38.72% decline year-over-year.
- Alto Neuroscience, Inc. investment income, interest for fiscal 2025 was $6.60M, a 25.40% decline from fiscal 2024.
- Alto Neuroscience, Inc. investment income, interest for fiscal 2024 was $8.85M, a 276.80% increase from fiscal 2023.
- Alto Neuroscience, Inc. investment income, interest for fiscal 2023 was $2.35M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.11M 10-Q · filed 2026-08-12 | $3.67M 10-Q · filed 2026-08-12 | $5.23M derived: sum of 3 quarters · filed 2026-08-12 | $6.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-13 | $3.12M derived: sum of 2 quarters · filed 2026-05-13 | $4.65M derived: sum of 3 quarters · filed 2026-05-13 | $6.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.09M derived: sum of 2 quarters · filed 2026-03-16 | $4.78M derived: sum of 3 quarters · filed 2026-08-12 | $6.60M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.53M 10-Q · filed 2025-11-12 | $3.21M derived: sum of 2 quarters · filed 2026-08-12 | $5.04M 10-Q · filed 2025-11-12 | $7.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-12 | $3.51M 10-Q · filed 2026-08-12 | $5.64M derived: sum of 3 quarters · filed 2026-08-12 | $8.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-13 | $3.96M derived: sum of 2 quarters · filed 2026-05-13 | $6.46M derived: sum of 3 quarters · filed 2026-05-13 | $9.12M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $4.63M derived: sum of 2 quarters · filed 2026-03-16 | $7.29M derived: sum of 3 quarters · filed 2026-03-16 | $8.85M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.50M 10-Q · filed 2025-11-12 | $5.16M derived: sum of 2 quarters · filed 2025-11-12 | $6.72M 10-Q · filed 2025-11-12 | $7.45M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.66M 10-Q · filed 2025-08-13 | $4.22M 10-Q · filed 2025-08-13 | $4.95M derived: sum of 3 quarters · filed 2025-08-13 | $5.67M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.56M 10-Q · filed 2025-05-14 | $2.30M derived: sum of 2 quarters · filed 2025-05-14 | $3.01M derived: sum of 3 quarters · filed 2025-05-14 | $3.68M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.45M derived: sum of 2 quarters · filed 2025-03-20 | $2.12M derived: sum of 3 quarters · filed 2025-03-20 | $2.35M 10-K · filed 2025-03-20 |
| 2023-09-30 | $714.00K 10-Q · filed 2024-11-12 | $1.38M derived: sum of 2 quarters · filed 2024-11-12 | $1.61M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $667.00K 10-Q · filed 2024-08-13 | $897.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $230.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |